Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02424305 · ClinicalTrials.gov registry record · Phase 1
Pharmacokinetics of LEO 43204 Gel in Actinic Keratosis Administered Under Maximal Use Conditions
A Phase 1 study, sponsored by LEO Pharma.
- Completed
- Registry status
- Phase 1
- Development phase
- 60
- Enrollment target
NCT02424305 is a Phase 1 study that has completed, run by LEO Pharma. The registered enrollment target is 60 participants.
The verdict
NCT02424305, a Phase 1 study, has completed, sponsored by LEO Pharma.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 60 participants
- Enrollment target
Study Summary
This is an open-label, uncontrolled, non-randomised multi-centre trial in which 3 parallel groups will be enrolled. The trial includes three active treatment groups. To be eligible for inclusion in this trial, subjects must have at least 15 clinically typical, visible, and discrete actinic keratosis (AKs) on the face, scalp or on the arm within a contiguous area of approximately 250 cm2 of sun-damaged skin. There will be 3 treatment groups: (1) once daily application of LEO43204 gel 0.018% on the full face for three consecutive days, (2) once daily application of LEO43204 gel 0.1% on the arm on a treatment area of approximately 250 cm2 for three consecutive days and , (3) once daily application of LEO43204 gel 0.037 % on the scalp for three consecutive days.
Interventions
- DRUG LEO 43204 gel 0.018%
- DRUG LEO 43204 gel 0.1%
- DRUG LEO 43204 gel 0.037%
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2015-05 |
| Est. Completion | 2015-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02424305
The ClinicalTrials.gov registry entry for NCT02424305 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is LEO Pharma, which has 65 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which LEO 43204 gel 0.018% is the first listed.
NCT02424305 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02424305 about?
NCT02424305 is a clinical study titled "Pharmacokinetics of LEO 43204 Gel in Actinic Keratosis Administered Under Maximal Use Conditions". This is an open-label, uncontrolled, non-randomised multi-centre trial in which 3 parallel groups will be enrolled. The trial includes three active treatment groups. To be eligible for inclusion in this trial, subjects must have at least 15 clinically typical, visible, and discrete actinic keratosis...
What is the current status of trial NCT02424305?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 60 participants. The study started on 2015-05. Estimated completion is 2015-07.
What interventions are being tested in trial NCT02424305?
The interventions under investigation include: LEO 43204 gel 0.018% (DRUG), LEO 43204 gel 0.1% (DRUG), LEO 43204 gel 0.037% (DRUG).
Who is sponsoring clinical trial NCT02424305?
This trial is sponsored by LEO Pharma, which has 65 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.